BEGIN:VCALENDAR
PRODID:-//github.com/ical-org/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:STANDARD
DTSTART:20241103T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11
TZNAME:EST
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250309T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3
TZNAME:EDT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Chronic liver disease is a major cause of morbidity and mortal
 ity both worldwide and in the United States (U.S.). Mortality due to live
 r cirrhosis has increased over the last 20 years in the U.S. and have per
 sisted despite epidemiologic shifts in the underlying causes of liver dis
 ease. Furthermore\, chronic liver disease has a substantial impact on you
 ng and middle-aged individuals in their prime\, with more than half of de
 aths attributable to chronic liver disease occurring before age 65. The c
 ost of liver disease in the U.S. is estimated to reach $32.5 billion per 
 year in 2026. For these reasons\, reducing deaths due to liver cirrhosis 
 is one of the goals of Healthy People 2030 . Trends in Connecticut have f
 ollowed the national pattern. The major risk factors for liver disease ar
 e viral hepatitis (HBV\, HCV\, HDV\, HEV)\, hazardous alcohol use\, metab
 olic disease. In most cases\, progression of chronic liver disease can be
  prevented. Chronic liver disease can be approached with the typical prev
 ention framework: primary prevention to mitigate the above-mentioned risk
  factors and avoid development of chronic liver disease\; secondary preve
 ntion in patients with established liver disease to prevent its progressi
 on toward cirrhosis or liver cancer\; and tertiary prevention to ameliora
 te the negative consequences of cirrhosis\, for example\, screening for l
 iver cancer and treating portal hypertension. Unfortunately\, most of the
  care currently provided to patients with chronic liver disease occurs in
  the final stages of illness: decompensated cirrhosis and liver cancer. T
 hus\, most of our activity focuses on conditions that represent the failu
 re of all three stages of prevention. We aim to reverse this trend and be
 lieve that preventative measures can be implemented through collaboration
  with health service providers and communities. We propose this collabora
 tive event to begin a dialogue about community-level prevention of chroni
 c liver disease between Yale Liver Center members and physicians\, commun
 ity physicians and the Department of Public Health (DPH). The overarching
  goal is to marry the expertise in liver disease and novel paradigms in l
 iver disease prevention and detection with the public health messaging an
 d implementation expertise of the DPH to improve prevention\, diagnosis\,
  and management of chronic liver disease in Connecticut.\n\nSpeakers:\nMa
 rio Strazzabosco\; Michael Nathanson\; Bubu Banini\; Joseph Lim\; Catheri
 ne Mezzacappa\; Lamia Haque\; Basile Njei\; Manisha Juthani\; Debora Bran
 don\; Lynn Sosa\; Lawrence Young\; Julienne Giard\; Venesha Heron\n\nAdmi
 ssion:\nFree\n\nFood:\nLunch\, Snacks\n\nDetails URL:\nhttps://medicine.y
 ale.edu/event/community-level-liver-disease-prevention-yale-liver-center-
 and-ct-department-of-public-health/\n
DTEND;TZID=America/New_York:20250828T173000
DTSTAMP:20260720T203050Z
DTSTART;TZID=America/New_York:20250828T113000
LOCATION:URL: https://yale.zoom.us/j/94697784358?pwd=aPoQuiCrwvEJGPAiQyyVg
 3xzLMh0Cn.1
SEQUENCE:0
STATUS:Confirmed
SUMMARY:Community Level Liver Disease Prevention
UID:69604832-b44b-43d7-a7af-28d0d6b593b7
END:VEVENT
END:VCALENDAR